A Hospital Study of QueaseEASE™ for PONV
In a descriptive assessment of the effects of QueaseEASE as a post-operative antiemetic, QueaseEASE was administered as an inhalant to 114 patients undergoing surgery at a hospital in the Northeast United States. Over 9-months, patients who experienced nausea with surgery received QueaseEASE during surgery and/or immediately after awakening in the PACU. Standard antiemetics were given intraoperatively only for patients receiving general anesthesia. If nausea occurred, QueaseEASE was administered as first line therapy. The patient was instructed to take 3-4 deep breaths through the nose with the EO held under his/her nose. If nausea was unresolved, pharmaceutical antiemetics were administered. Of 114 subjects, 38 (33.3%) required additional post-operative antiemetics, whereas 66.7% of subjects (n=76) had their nausea resolved with QueaseEASE alone.
Of the 114 subjects, 74 (64.9%) were female. Twenty three (20.2%) were women undergoing a C-section for first time delivery (N=21) or repeat delivery (N=2). Of the women having a C-section, 4 (17.4%) had additional anti-emetics administered, while 19 (82.6%) required no further anti-emetics. This subpopulation had the highest “success” rate with the QueaseEASE. In contrast, patients undergoing ear, nose and throat and pelvic surgeries had the highest rate of additional postop antiemetic use (71.4%, 50% respectively, Table 3). Although the relationship between gender and use of additional anti-emetics was not significant (c2=1.23, p=.27), 40% of men required additional antiemetic use versus 29.7% of women. Differences among procedures were close to significant (c2=10.52, p=.06), and may partly be explained by gender differences in obstetrics surgery. The study data indicated that QueaseEASE provided a substantial benefit to all patient populations in regards to reducing or eliminating PONV.
Table 1. Characteristics of Postoperative Patients using QueaseEASE with/without additional anti-emetics
|
QueaseEASE Alone |
QueaseEASE + |
Analysis |
P value |
Gender N ( %) |
|
|
c2 =1.23 |
p=.27 |
Female |
52 (70.3) |
22 (29.7) |
|
|
Male |
24 (60.0) |
16 (40.0) |
|
|
Age (7-89 yrs) |
|
|
T112 =.54 |
p=.59 |
Mean(SD) |
46.9 (22.0) |
44.5 (22.9) |
|
|
N |
76 |
38 |
|
|
Procedure N(%) |
|
|
c2 =10.52 |
p=.06 |
Orthopedic |
26 (66.7) |
13 (33.3) |
|
|
C-Section |
19 (82.6) |
4 (17.4) |
|
|
Abdominal |
20 (64.5) |
11 (35.5) |
|
|
Pelvic |
5 (50.0) |
5 (50.0) |
|
|
ENT |
2 (28.6) |
5 (71.4) |
|
|
Other |
4 (100.0) |
0 (0) |
|
|
Anesthesia type |
|
|
c2 =2.14 |
P=.14 |
Regional/Spinal |
45 (72.6) |
17 (27.4) |
|
|
General |
31 (59.6) |
21 (40.4) |
|
|